Yearly Archive

Yearly Archives: 2022

February 7, 2022 no comments

Re-Imagining Med Chem Strategies: the Tyranny of the n+1 Compound

Finding small molecule drugs is much harder than finding a needle in a haystack – discovering the right arrangement of atoms to bind precisely to a protein target to elicit a particular response is a problem of vast dimensionality.

We are most familiar with the numbers involved when dealing with antibodies: a typical antibody library might contain 1013 different clones – but even that hardly scratches the surface of the 1080 or so possible CDR sequences.  Choosing the sequences to populate a library is critical – and even today new innovations, such as the RxBiologics’ Galaxy™ platform, are dramatically improving the output.

Yet the situation with small molecules is even worse.  Chemists look on jealously at a universe of a mere 1080 possibilities for antibody CDRs!

So DrugBaron asked Nigel Ramsden, who heads up the RxChemistry team, whether the solution lies in bigger libraries and yet higher-throughput screening?

“In a word, no!  Bigger won’t cut it – even with a 10-fold increase in library size, you are still testing only the most miniscule fraction of all possible compounds.  We have to face facts – its NEVER going to be practical to test a material fraction of the universe of possibilities when it comes to small molecules

So the answer has to lie in quality rather than quantity.  Which molecules to test, not how many.

In exactly, the same way Galaxy™ advanced antibody discovery by being smart about which clones to include in the starting library, we have to be smarter in choosing the molecules we test.”

So scaling up real, wet experimentation cannot improve efficiency in small molecule discovery.  But what about in silico searches – are they the answer to the fundamentaly dimensionality problem?  David Fox, Associate Professor of Chemistry at Warwick University and head of the RxChemistry medicinal chemistry team, thinks its only a small part of the solution:

“We can scale in silico searches well beyond the practical limits of any physical high throughput screen.  But even processor time is not infinite and free, so searching ‘everything’ remains well outside the realm of possibilities

And on top of that, in silico searches (like physical screening) are imperfect filters – there are lots of false positives.  So you would need to make many of the in silico hits to find one with the desired profile in a real experiment.  Given that, there is no point including compounds in in silico libraries that are difficult or impossible to make

Instead, we need to increase the diversity of the compounds we do screen (whether in silico or for real).  Right now, both virtual and real libraries are dominated by particular …

More
May 24, 2021 no comments

Why Small Beats Big: the Hidden Cost of Too Many Voices

The coronavirus pandemic has taught us a lot …

More
February 16, 2021 no comments

The history – and the future – of antibody discovery technologies

Monoclonal antibodies are now well-established as a mainstay …

More
January 8, 2021 no comments

Why Sarepta’s most recent failure in DMD was entirely predictable

Yesterday, Sarpeta (NASDAQ: $SRPT) announced that its gene …

More
January 2, 2021 no comments

One dose or two? What the debate about COVID vaccination teaches us about science – and its limitations

Over the past week a furious debate has …

More
November 9, 2020 no comments

The Hidden Superpower of Strategic Focus

The first death unequivocally caused by COVID was reported to …

More
April 14, 2020 no comments

COVID19: Serology is harder than it looks

More than a month after the World Health …

More
January 24, 2018 no comments

The Cult Of DNA-centricity

  Understanding the role of DNA in biology is …

More
October 21, 2014 no comments

D&D On R&D – Lessons For Pharma From The Dungeon Master

The discovery and early development phases of pharmaceutical …

More
April 16, 2014 comments

An open letter to Congressman Waxman on the subject of drug pricing

Dear Congressman Waxman (and anyone else concerned about …

More

Yearly Archive